Epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia

Aim. To study the clinical and demographic profile of patients with non-metatstatic castration-resistant prostate cancer (nmCRPC) and clinical approaches to the treatment of nmCRPC in the context of daily medical practice before and after progression M1 stage.

Materials and methods. The multicenter non-interventional epidemiological study were included 200 patients with a documented diagnosis of nmCRPC from 2019 to 2020. Each patient visited twice: start and after 6 months. Of the 200 patients included, 9 were excluded from the analysis presented in this article: 1 patient had no information on inclusi- on criteria, 1 patient did not meet the inclusion criteria, 7 patients did not attend visit 2. Thus, data are presented for 191 patients.

Results and conclusion. The median age was 74.3 years (range 55 to 91). 72 % (137/191) had a disability group. The most common comorbidities were hypertension (n = 115) and hypercholesterolemia (n = 56). The median time from the diagnosis of prostate cancer to the development of castration resistance (diagnosis of nmCRPC) was 75 months. Prostate specific antigen (PSA) nadir (0.37 ng/ml on average) was achieved after 15 months of prostate cancer therapy (median time to reach PSA nadir). At the same time, PSA doubling time in most cases (47.6 %; 91/191) was less than 6 months, 18.8 % of persons (36/191) had PSA doubling time for more than 10 months.

1. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019;10(2):63–89. DOI: 10.14740/wjon1191

2. Simone G. The Epidemiology of prostate cancer. In: Prostate Cancer. Eds.: S.R.J. Bott, K.L. Ng. Australia, Brisbane: Exon Publications. DOI: 10.36255/exonpublications.prostatecancer.epidemiology.2021

3. Mottet N., Cornford P., van den Bergh R.C.N. et al. EAUESTRO‑SIOG Guidelines on Prostate Cancer. Eur Urol 2018. Available at: https://uroweb.org/guideline/prostatecancer.

4. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492

5. Thurin N.H., Rouyer M., Gross‑Goupil M. et al. Epidemiology of metastatic castration‑resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol 2020;69:101833. DOI: 10.1016/j.canep.2020.101833

6. Wallace K.L., Landsteiner A., Bunner S.H. et al. Increasing prevalence of metastatic castration‑resistant prostate cancer in a managed care population in the United States. Cancer Causes Control 2021;32(12):1365–74. DOI: 10.1007/s10552‑021‑01484‑4

7. Ferlay J.E.M., Lam F., Colombet M. et al. Global cancer observatory: cancer tomorrow. Lyon, France: International Agency for Research on Cancer. Available at: https://gco.iarc.fr/tomorrow.

8. State of oncological care in Russia in 2020. Eds.: А.D. Kaprin, V.V. Starinskiy, A.О. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 239 p. (In Russ.).

9. Reva S.A., Nosov А.K., Korol V.D. et al. Comparison of treatment results for patients with high‑risk prostate cancer according to the EAU and NCCN criteria. Onkourologiya = Cancer Urology 2021;17(2):54–61. (In Russ.). DOI: 10.17650/1726‑9776‑2021‑172‑54‑61

10. Somov A.N., Suslin S.A. Prostate cancer. Epidemiology, risk factors and early detection. Profilakticheskaya meditsina = Preventive Medicine 2020;23(3):149–55. (In Russ.). DOI: 10.17116/profmed202023031149

11. Ahdoot M., Wilbur A.R., Reese S.E. et al. MRI‑targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 2020;382(10):917–28. DOI: 10.1056/NEJMoa1910038

12. Alekseev B.Ya., Krasheninnikov A.A., Nyushko K.M. et al. Surgical treatment of patients with high‑risk prostate cancer: long‑term outcomes and prognostic factors. Onkourologiya = Cancer Urology 2020;16(4):99–111. (In Russ.). DOI: 10.17650/1726‑9776‑2020‑16‑4‑99‑111

13. American Cancer Society. Cancer Facts & Figures. Available at: https://www.cancer.org/content/dam/cancer‑org/research/cancer‑facts‑and‑statistics/annual‑cancerfacts‑and‑figures/2020/cancerfactsand‑figures‑2020.pdf.

14. Kirby M., Hirst C., Crawford E.D. Characterising the castration‑resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92. DOI: 10.1111/j.1742‑1241.2011.02799.x

15. Leeman J.E., Chen M.H., Huland H. et al. Advancing age and the odds of upgrading and upstaging at radical prostatectomy in men with Gleason score 6 prostate cancer. Clin Genitourin Cancer 2019;17(6):e1116–21. DOI: 10.1016/j.clgc.2019.07.018

16. Alchin D.R., Murphy D., Lawrentschuk N. Risk factors for Gleason score upgrading following radical prostatectomy. Minerva Urol Nefrol 2017;69(5):459–65. DOI: 10.23736/S0393‑2249.16.02684‑9

17. Zharinov G.M., Bogomolov O.A. The pretreatment prostatespecific antigen doubling time: clinical and prognostic values in patients with prostate cancer. Onkourologiya = Cancer Urology 2014;10(1):44–8. (In Russ.). DOI: 10.17650/1726‑97762014‑10‑1‑44‑48

18. Milecki P., Antczak A., Martenka P., Kwias Z. What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision‑making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer? Cent European J Urol 2011;64(2):67–70. DOI: 10.5173/ceju.2011.02.art3

19. Howard L.E., Moreira D.M., De Hoedt A. et al. Thresholds for PSA doubling time in men with non‑metastatic castration‑resistant prostate cancer. BJU Int 2017;120(5B):E80–6. DOI: 10.1111/bju.13856

20. Smith M.R., Cook R., Lee K.A., Nelson J.B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‑resistant nonmetastatic prostate cancer. Cancer 2011;117(10):2077–85. DOI: 10.1002/cncr.25762

21. Liede A., Arellano J., Hechmati G. et al. International prevalence of nonmetastatic (M0) castration‑resistant prostate cancer (CRPC). J Clin Oncol 2013;31(15_suppl): e16052. DOI: 10.1200/jco.2013.31.15_suppl.e16052

22. Parker C., Castro E., Fizazi K. et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‑up. Ann Oncol 2020;31(9):1119–34. DOI: 10.1016/j.annonc.2020.06.011

23. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53(1):68–80. DOI: 10.1016/j.eururo.2007.09.002

24. Nosov D.A., Volkova M.I., Gladkov O.A. et al. Practical recommendations for the drug treatment of prostate cancer. Zlokachestvennye opukholi: Prakticheskie rekommendatsii RUSSCO #3s2 = Malignant Tumors: RUSSCO Practical Guidelines #3s2, 2020;10:33. (In Russ.).

25. Clinical Guidelines. Prostate cancer. Ministry of Health of Russia, 2020. 142 p. (In Russ.).

26. Smith M.R., Saad F., Chowdhury S. et al. Apalutamide treatment and metastasis‑free survival in prostate cancer. N Engl J Med 2018;378(15):1408–18. DOI: 10.1056/NEJMoa1715546

27. Smith M.R., Saad F., Chowdhury S. Apalutamide and overall survival in prostate cancer. Eur Urol 2021;79(1):150–8. DOI: 10.1016/j.eururo.2020.08.011

28. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castration‑resistant prostate cancer. N Engl J Med 2018;378(26):2465–74. DOI: 10.1056/NEJMoa1800536

29. Sternberg C.N., Fizazi K., Saad F. Enzalutamide and survival in nonmetastatic, castration‑resistant prostate cancer. N Engl J Med 2020;382(23):2197–206. DOI: 10.1056/NEJMoa2003892